Fully modified tcDNA-ASOs can also be used to promote exon-inclusion and a typical example is the re-inclusion of the exon 7 of the SMN2 gene as a therapeutic strategy for the treatment of SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.